# EDGAR Filing Document

**Accession Number:** 0001657045
**File Stem:** 0001641172-25-017123
**Filing Date:** 2025-6
**Character Count:** 79838
**Document Hash:** 8938678e5ecd8799f7f2dc6e4da946d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-017123.hdr.sgml**: 20250630

**ACCESSION NUMBER**: 0001641172-25-017123

**CONFORMED SUBMISSION TYPE**: 10-Q/A

**PUBLIC DOCUMENT COUNT**: 51

**CONFORMED PERIOD OF REPORT**: 20240331

**FILED AS OF DATE**: 20250630

**DATE AS OF CHANGE**: 20250630

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEXT-ChemX Corporation.
- **CENTRAL INDEX KEY:** 0001657045
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS CHEMICAL PRODUCTS [2890]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 320446353
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56379
- **FILM NUMBER:** 251091847

**BUSINESS ADDRESS:**
- **STREET 1:** 901 MOPAC EXPRESSWAY SOUTH BUILDING 1
- **STREET 2:** SUITE 300
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78746
- **BUSINESS PHONE:** 512-663-2690

**MAIL ADDRESS:**
- **STREET 1:** 901 MOPAC EXPRESSWAY SOUTH BUILDING 1
- **STREET 2:** SUITE 300
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78746

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AllyMe Group, Inc./NV
- **DATE OF NAME CHANGE:** 20181227

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Wewin Group Corp.
- **DATE OF NAME CHANGE:** 20170803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Makh Group Corp.
- **DATE OF NAME CHANGE:** 20151029

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q/A**

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the quarterly period ended: **<u>March 31, 2024</u>**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from ____________ to _____________

Commission File Number: **000-56379**

**<u>NEXT-ChemX Corporation</u>**

(Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| **Nevada** | **32-0446353** |
| (State or other jurisdiction<br> of incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

**1980 Festival Plaza Drive, Summerlin South, 300,** 

**Las Vegas, Nevada 89135**

(Address of principal executive offices, Zip Code)

**(725) 867-0789**

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **N/A** | **N/A** | **N/A** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐ No ☒

The number of shares outstanding of each of the issuer's classes of common stock, as of June 27, 2025 is as follows:

---

| | |
|:---|:---|
| Class of Securities | Shares Outstanding |
| Common Stock, $0.001 par value | 28546834 |

---

IMPORTANT NOTICE

On May 3, 2024, the Company was made aware that its long standing auditors, BF Borgers CPA PC, had been denied the privilege of appearing or practicing before the Securities and Exchange Commission (the "SEC") as an accountant. In view of the nature of the actions taken by the SEC in relation to the Company's former auditor, the SEC required the Company to have its new auditors review 2 years of its quarterly financial statements along with the reaudit of 2 years of annual financial statements. This has resulted in a deficiency in the Company's filings entirely due to circumstances beyond the control of the Company. The Company appointed a new registered public accounting firm: Fruci & Associates II PLLC, Certified Public Accountants based in Spokane, Washington ("Fruci & Associates") to replace BF Borgers.

This present Quarterly Report filed on Form 10-Q/A (the "Report") includes modifications resulting from the completion of the audit carried out by Fruci & Associates on the Company's 2023 Annual Report filed on Form 10-K/A on April 28, 2025 as well as the review of the present restated Report and is duly filed in replacement of the original July 15, 2024 filing.

The principal change to the 10-Q are as follows:

Two important adjustments were made to the Company's financial statements: 1) the Company's technology, considered in filings since September 2021 to be an indefinite intangible asset was reevaluated and is now considered to have an estimated useful life equivalent to the period of its underlining patent protection, appropriate amortization being charged to the value of the asset accordingly. This has resulted in an adjustment of $495,592 to the asset value as of March 31, 2024. This has resulted in a charge of $187,227 against the value of the asset as amortization; and 2) the balance sheet was readjusted to include $308,365 of retained earnings.

On the Company's condensed balance sheet, the Company will now report any "Commitments and Contingencies" as a separate line item.

Generally, the Report has been made consistent with the Company's 2023 Annual Report filed on Form 10-K/A on April 28, 2025 and with the introduction of small changes in presentation and with some greater detail to improve disclosure.

Matters relating to projected timing in the Report have been changed from the original disclosure better to reflect the current belief of management regarding such projections. Where necessary or helpful, the circumstances relating to the need for such adjustment are also reported.

A number of other changes were made to punctuation and grammar that do not affect the sense of disclosure, and where dollar figures included cents, these were rounded up to the nearest dollar.

**NEXT-ChemX Corporation**

![](logo_001.jpg)

***Quarterly Report on Form 10-Q/A***

***For the Quarter Ended March 31, 2024***

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **[PART I – FINANCIAL INFORMATION](#mi_001)** | **[PART I – FINANCIAL INFORMATION](#mi_001)** |  |
| Item 1. | [Financial Statements](#mi_002) | F-2 |
| Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#mi_008) | 3 |
| Item 3. | [Quantitative and Qualitative Disclosures About Market Risk](#mi_009) | 5 |
| Item 4. | [Controls and Procedures](#mi_010) | 5 |
| **[PART II – OTHER INFORMATION](#mi_011)** | **[PART II – OTHER INFORMATION](#mi_011)** |  |
| Item 1. | [Legal Proceedings](#mi_012) | 6 |
| Item 1A. | [Risk Factors](#mi_013) | 7 |
| Item 2. | [Unregistered Sale of Equity Securities and Use of Proceeds](#mi_014) | 7 |
| Item 3. | [Defaults Upon Senior Securities](#mi_015) | 7 |
| Item 4. | [Mine Safety Disclosures](#mi_016) | 7 |
| Item 5. | [Other Information](#mi_017) | 7 |
| Item 6. | [Exhibits](#mi_018) | 7 |
| [Signatures](#mi_019) | [Signatures](#mi_019) | 8 |

---

**Caution Regarding Forward-Looking Information**

This Quarterly Report on Form 10-Q/A, including, without limitation, statements containing the words "believes", "anticipates", "expects" and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.

Given these uncertainties, readers of this Form 10-Q/A and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

**NEXT-CHEMX CORPORATION**

**INTERIM FINANCIAL STATEMENTS**

**Table of Contents**

---

| | |
|:---|:---|
|  | **Page** |
| [Condensed balance sheets as of March 31, 2024 (restated) and December 31, 2023 (audited)](#mi_003) | F-2 |
| [Condensed Statements of Operations for the three months ended March 31, 2024 (restated) and 2023 (unaudited)](#mi_004) | F-3 |
| [Condensed Statements of Changes in Stockholders' Equity (Deficit) for the three months ended March 31, 2024 (restated) and 2023 (unaudited)](#mi_005) | F-4 |
| [Condensed Statements of Cash Flows for the three months ended March 31, 2024 (restated) and 2023 (unaudited)](#mi_006) | F-5 |
| [Notes to Unaudited Condensed Financial Statements](#mi_007) | F-6 |

---

**PART I**

**<u>FINANCIAL INFORMATION</u>**

**ITEM 1. FINANCIAL STATEMENTS**

**NEXT-ChemX Corporation**

Condensed Balance Sheets

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br>**2024**<br>**(restated)** | **December 31,**<br>**2023**<br>**(audited)** |
| **ASSETS** |  |  |
| Current Assets: |  |  |
| Cash | $94770 | $2458 |
| Financial Assets | 44957 | 64944 |
| Prepaid expense and other current assets | 77103 | 72925 |
| Total Current Assets | 216830 | 140327 |
| Property and equipment, net | 11287 | 12621 |
| Intangible asset, net | 2654522 | 2691967 |
| Total Non-current Assets | 2665809 | 2704588 |
| **Total Assets** | $2882639 | $2844915 |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |
| Current Liabilities: |  |  |
| Accounts payable and accrued liabilities | $2632132 | $2443207 |
| Other Current Liabilities | 511980 | 511980 |
| Loan payable | 965000 | 945000 |
| Due to related party | 52445 | 32238 |
| Total Current Liabilities | 4161557 | 3932425 |
| Non-Current Liabilities: |  |  |
| Notes payable | 365000 | - |
| Total Non-Current Liabilities | 365000 | - |
| Total Liabilities | $4526557 | $3932425 |
| Commitments and Contingencies |  |  |
| Stockholders' Equity (Deficit): |  |  |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued and outstanding |  |  |
| Common stock, $0.001 par value, 100,000,000 shares authorized, 28,546,834 issued and outstanding | 28547 | 28547 |
| Additional paid-in capital | 5396053 | 5396053 |
| Accumulated deficit | (7068518) | (6512110) |
| Total Stockholders' Equity (Deficit) | (1643918) | (1087510) |
| **Total Liabilities and Stockholders' Equity (Deficit)** | $2882639 | $2844915 |

---

The accompanying notes are an integral part of these condensed financial statements.

**NEXT-ChemX Corporation**

Condensed Statements of Operations

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2024**<br>**(restated)** | **2023**<br>**(unaudited)** |
| Revenues | $- | $- |
| Operating expenses |  |  |
| &nbsp;&nbsp;&nbsp;Salaries and Employee Benefits | 237609 | 256500 |
| &nbsp;&nbsp;&nbsp;Professional fees and contractors | 200100 | 129204 |
| &nbsp;&nbsp;&nbsp;Depreciation and Amortization | 38780 | 1334 |
| &nbsp;&nbsp;&nbsp;Other operating Expenses | 43092 | 49615 |
| Total operating expenses | 519581 | 436653 |
| Income (loss) from operations | (519581) | (436653) |
| Other income (expense) |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | (36827) | (21320) |
| Total other expense | (36827) | (21320) |
| **Net income (loss)** | $**(556408)** | $**(457973)** |
| Net gain (loss) per common share: Basic and diluted | $(0.02) | $(0.02) |
| Weighted average number of common shares outstanding: Basic and diluted | 28546834 | 28374612 |

---

The accompanying notes are an integral part of these condensed (unaudited) financial statements.

**NEXT-ChemX Corporation**

Condensed Statements of Changes in Stockholders' Equity (Deficit)

(unaudited)

**For the Three Months Ended March 31, 2024 (restated)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount<br>** | **Additional Paid-in**<br>**Capital<br>** | **Accumulated**<br>**Deficit** | **Stockholders'**<br>**Deficit** |
| **Balance December 31, 2023** | 28546834 | $28547 | $5396053 | $(6512110) | $(1087510) |
| Net loss |  |  |  | (556408) | (556408) |
| **Balance March 31, 2024** | 28546834 | $28547 | 5396053 | $(7068518) | $&nbsp;&nbsp;&nbsp;&nbsp;(1643918) |

---

**For the Three Months Ended March 31, 2023 (unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Additional Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Stockholders'**<br>**Deficit** |
| **Balance December 31, 2022** | 28346834 | $28347 | $4396253 | $(3692732) | $731868 |
| Stock Issuances to 3rd Party | 100000 | 100 | 499900 |  | 500000 |
| Net loss |  |  |  | (457973) | (457973) |
| **Balance March 31, 2023** | 28446834 | $28447 | 4896153 | $(4150705) | $773895 |

---

The accompanying notes are an integral part of these condensed (unaudited) financial statements.

**NEXT-ChemX Corporation**

Condensed Statements of Cash Flows

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2024**<br>**(restated)** | **2023**<br>**(unaudited)** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| Net income(loss) | $(556408) | $(457973) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 38780 | 1334 |
| &nbsp;&nbsp;&nbsp;Unrealized loss on trading securities | 19987 |  |
| &nbsp;&nbsp;&nbsp;Changes in Operating Assets and Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related Party Advances | 20207 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | (4178) | 8839 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 188924 | 137655 |
| **Net cash provided by (used in) operating activities** | (292688) | (310145) |
| **INVESTING ACTIVITIES** |  |  |
| Purchase of property and equipment | - | - |
| **Net cash provided by (used in) investing activities** |  |  |
| **FINANCING ACTIVITIES** |  |  |
| Proceeds from the Stock Issuance of Common Stocks |  | 500000 |
| Net proceeds from notes payable | 365000 | 75000 |
| Net proceeds from loan payable | 20000 |  |
| Repayment of notes payable | - | (151007) |
| **Net cash provided by (used in) financing activities** | 385000 | 423993 |
| **Net increase (decrease) in cash** | 92312 | 113848 |
| **Cash, beginning of year** | 2458 | 28355 |
| **Cash, end of the period** | $94770 | $142203 |
| **SUPPLEMENTAL DISCLOSURES:** |  |  |
| **Cash paid during the period for:** |  |  |
| Income tax | $- | $- |
| Interest | $- | $- |

---

The accompanying notes are an integral part of these condensed (unaudited) financial statements.

**NEXT-ChemX Corporation**

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2024

**NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS**

**Organization and Description of Business**

NEXT-ChemX Corporation, formerly known as AllyMe Group Inc. ("Company", "we" or "us") was incorporated under the laws of the State of Nevada on August 13, 2014, and has adopted a December 31 fiscal year end. The Company trades on the OTC market (Pink Sheet) under the symbol "CHMX". On December 23, 2021, the Company filed SEC Form 8-12G becoming a mandatory filer and has since complied with the reporting requirements of the Securities Exchange Commission as a reporting issuer.

Since April 2021, following a complete change of the Company's shareholders, management, assets and strategy, the business of the Company is the commercialization of a novel innovative Ion-Targeting Continuous-Flow Direct Extraction Technology ("iTDE Technology") as further described in Note 5 below. The iTDE Technology is embodied in certain patents and patent applications as well as proprietary knowledge.

The primary focus of the Company is the commercial launch of its iTDE Technology in a scalable system, deployable remotely to customer locations, which will enable the commercial extraction of lithium from natural brines and geothermal sources as well as liquors from leached mined ore solutions. In addition, during the first quarter, management began to focus on developing two to three other targeted systems for the mining of metals as well as water treatment systems and recycling.

Potential future commercial applications for the iTDE Technology include:

● Extracting Fatty Acids from Vegetable Oils for More Economical Refining;

● Extracting of Radioactive Ions from Nuclear Plant Stored Water;

● Extracting of Metal Ions from Mine Leach Solutions, Effluent, or Tailings; and

● Desalination of Sea Water, by Extracting Ions for Water Purification

During the first quarter of 2024, the Company has continued to manage the construction of the first of two pilot plant systems that will form the basis of its ongoing commercialization efforts by demonstrating the scalability of the system for commercial purposes, by providing actual commercial data to define typical running costs, and by generating commercial interest by processing samples supplied by potential customers to demonstrate the iTDE technology's capability commercially. The two planned systems include (i) a smaller flexible system utilizing the iTDE Technology that will enable the processing of solutions containing lithium to demonstrate the commercial viability of the system; and (ii) a larger system that will handle the processing of industrial quantities of brines, better demonstrating the scalability and performance of the system when used commercially to extract lithium. This work is being carried out in India under contract.

The smaller system was designed to facilitate work on refinement of the basic iTDE system by enabling changes to sensor types and positions as well as adaptations to its other relevant systems. It is expected this will contribute to improvements in efficiency and assist in the modelling of the process for commercial implementation, enabling changes that will reduce the cost and improve the economics of the process. The inherent flexibility of the design also allows the Company to conduct its research into the extraction of other elements thereby exploring the commercial viability of the extraction of other elements.

The first system is expected to be completed during third quarter of 2025.

The Company anticipates first running extraction tests on brine solutions mixed with controlled defined quantities of elements that approximate the naturally occurring brines of potential customers. The Company has already received brine samples from Clontarf Energy plc, a UK AIM listed company with whom the Company concluded an agreement to iTDE Technology in Bolivia through a jointly established commercial venture. The composition of these brines will be the basis for modeling these controlled samples. This initial calibration of the system will be done by making synthetic brines based upon analytical data received from the Bolivian State Lithium Company and should provide a basis for better testing with actual brines. We expect large container sized sample of actual brines to arrive in India around October of 2024 for testing in our pilot plant system.

We have also engaged with another Indian company to test the effectiveness of their nano-filtration system to use in front of our pilot plant system to remove significant amounts of divalent ions, such as magnesium and calcium, without the use of any chemicals. This may make our complete system more economical in challenging remote areas such as our project with Clontarf in Bolivia.

Due to a lack of funding, the Company has scaled back its intellectual property protection strategy in the near term.

**NOTE 2 – GOING CONCERN**

The Company has incurred losses since inception (August 13, 2014) resulting in an accumulated deficit of $7,068,518 as of March 31, 2024. The Company has been operating with a working capital deficit since changing its business focus in April 2021. For a variety of reasons, the Company has found it difficult to raise money on the capital markets and has relied extensively on existing shareholders to fund operating expenses. Such funding has been insufficient necessitating the Company's employees and on occasion its third party contractors to settle for delays in payment. In the case of employees and consultants, a significant amount of debt has accumulated effectively becoming a source of the Company's operating capital. To achieve revenues, the Company should complete its pilot plant enabling it to demonstrate the commercial benefits of the iTDE Technology. Until such time as the pilot plant is completed and the Company can commence the normal commercialization of its technology, further losses are anticipated. Management anticipates more losses before the commercialization of the system can be expected to break-even or to turn a profit. During fiscal 2023, the Company concluded agreements with a third party aimed at commercialization of the iTDE Technology and the Company believes that it will identify further similar opportunities once pilot demonstrations become a reality. This is expected to ease the deficit in working capital.

For the three months ended March 31, 2024, the Company showed a net loss of $556,408, as compared with the loss of $457,973 for the three months ended March 31, 2023. The net cash used in operating activities of the Company during the three months ended March 31, 2024, and 2023 was $292,688 and $310,145, respectively. Notwithstanding the receipt on April 21, 2023 of the first income from the commencement of the commercialization of the Company's main asset, its iTDE Technology, there remains a substantial doubt regarding the Company's ability to continue as a going concern. Management believes that the Company's capital requirements will depend on many factors including the continuing and expanding success of the Company's development efforts, however, it is anticipated that the Company will require additional capital.

From the anticipated receipts of any financing, the Company must discharge outstanding payables of $162,373 and a further $513,800 in accrued expenses together with a total of $1,955,959 in payables for salary, remuneration and expenses.

The Company will need to raise an estimated $3 million during fiscal 2024 to manage its business needs. There is no assurance that the financing of this nature will be available in the future. The possible inability to raise the financing necessary and the general business uncertainties and particular conditions and situation described above raise substantial doubt about our ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand, loans from directors and, or the private placement of common stock. There can be no assurances that management's plans will be successful.

**NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Interim Financial Statements*

The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim financial statements should be viewed in conjunction with the audited financial statements of the Company for the year ended December 31, 2023.

The financial statements are presented in United States dollars.

*Use of Estimates*

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

*Evaluation of Long-Lived Intangible assets*

The Company acquired its principal intellectual property asset in the second quarter of 2021. The value of the asset was initially derived from the underlying arms' length transaction in which the company owning the technology transferred the technology to the Company in exchange for a specific number of shares of Common Stock of the Company. The value of the shares was itself derived from that the fact that such shares were bought and sold in an arms' length transaction that occurred simultaneously. The technology composed initially of patents and patent applications as well as certain knowhow was initially amortized by the Company. However, during fiscal year 2021, due to the nature of the technology behind the asset and its application across multiple disciplines and businesses, Management considered the asset to be greater than the individual patents and possible patent applications. Certain technological ideas give rise to many various applications ('stem technologies'). For this reason, on September 30, 2021, the asset as a stem technology was reclassified as an intangible asset of indefinite life. The value taken was that of its book value at the third quarter end 2021 following initial amortization. Intangible assets of indefinite life are not amortized, but instead tested for impairment at least annually or more frequently if events and circumstances indicate that the asset might be impaired.

The Company is required to evaluate periodically the useful life of its assets and to adjust the value of the asset, depreciating it over its useful life. This revaluation has resulted in the decision to amortize the technology asset as a finite indefinite asset taking as its useful life the protection period of the patents filed to protect the said asset.

The indefinite intangible asset was reevaluated and is now considered to have an estimated useful life equivalent to the period of its underlining patent protection, appropriate amortization being charged to the value of the asset accordingly. This has resulted in an adjustment of $495,592 to the asset value as of March 31, 2024. This has resulted in a charge of $187,227 against the value of the asset as amortization; and 2) the balance sheet was readjusted to include $308,365 of retained earnings. Further details are included in Note 5 below.

*Revenue Recognition*

The Company utilizes a five-step process when assessing the recognition of revenue from contractual obligations.

&nbsp;&nbsp;&nbsp;&nbsp;(i) Identification of the type
 and binding nature of the contract as well as an identification and assessment of the goods and services undertaken with specific
 reference to the intangible nature of the intellectual property rights sold;

(ii) Identification of specific
 performance obligations within the overall contract that are distinct.

(iii) Determination of the specific
 price or value of the specific performance obligation.

(iv) Allocation of the transaction
 price or value of a specific performance obligation; and

(v) Determination of the moment
 the obligation undertaken is delivered or performance is satisfied.

*Earnings (loss) per Share*

Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net income available to common shareholders by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. Potentially dilutive shares of common stock consist of the common stock issuable upon the conversion of convertible debt, preferred stock and warrants. The Company uses the if-converted method to calculate the dilutive preferred stock and treasury stock method to calculate the dilutive shares issuable upon exercise of warrants.

For the quarterly periods ended March 31, 2024, and March 31, 2023, there were no potentially dilutive debt or equity instruments issued or outstanding and any such shares would have been excluded from the computation because they would have been anti-dilutive as the Company incurred losses in these periods.

*Investment Policy in Joint Ventures*

It is the policy of the Company to recognize joint ventures only once sufficient consideration has been received for the venture to impact its operations. Neither the execution of an agreement requiring the formation of a joint venture nor the creation of a shell intended to be the venture vehicle is considered sufficient. Once operations commence in a material manner, the Company will recognize the operation of a joint venture in its financial statements.

*PP&E depreciation policy of fixed tangible assets*

The depreciation policy of the Company's long term fixed tangible assets is decided dependent on the useful life a particular asset is expected to have. The Company currently operates with very few assets having no real estate and with very little operational equipment. The current book value of all fixed tangible assets owned by the Company is $11,287. None of these assets are considered to be material to the business.

*Recent accounting pronouncements*

The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company's financials properly reflect the change.

The Company has noted the recent issuance by FASB of ASU 2023-07 on November 27, 2023 that introduces amendments to "improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses" to enable "investors to better understand an entity's overall performance" and assess "potential future cash flows". At present, the Company has no marketable product lines, it is currently developing the technology that will enable the introduction of one or more such lines, however, it is too early to predict in what final product form, and more importantly how many different variations of this, the iTDE Technology will eventually be marketed. The Company's chief operating decision maker, its CEO Mr. Benton Wilcoxon, who is responsible for the allocation of the Company's resources acts on the principle that the business cannot as yet be considered to operate with different segments of activity nor is investment into development work divided into different segments, its operating capital and investment being dedicated only to one end, that of completion of the iTDE Technology and its incorporation into one or more final marketable product segments. For this reason, the Company does not feel ASU 2023-07 is currently applicable.

**NOTE 4 – PREPAID EXPENSE AND OTHER CURRENT ASSETS**

Prepaid expenses and other current assets amounted to $77,103 as of March 31, 2024, it was increased from the $72,925 reported as at December 31, 2023. This represents an increase of $4,178 during the period. Prepaid expenses comprise a $1,600 deposit on the rental of laboratory facilities and a $600 deposit under a consultancy agreement, both unchanged. The remainder comprises advance payments for the purpose of filing for intellectual property protection. Payments are made in trust to our IP attorneys through whom amounts are disbursed when required. The trust account is replenished when needed.

**NOTE 5 – RESTATEMENT OF THE COMPANY'S INTELLECTUAL PROPERTY ASSET**

The Company's principal asset is its iTDE Technology. This technology is now classified as a finite intangible asset and is amortized over the life of the technology's underlying patents.

Previously, from September 2021, the Company had classified its iTDE Technology as an indefinite intangible asset and therefore the asset was not amortized, however, during fiscal 2023, the Company reassessed its iTDE Technology, concluding that such technology was a finite, rather than infinite, intangible asset. As a result, the Company began to restate the value of the technology on its books by applying retroactive amortization to the value of the asset. The audited annual report of the Company for 2023 filed with the SEC on form 10-K/A on April 28, 2025 records the results of the reevaluation and this Report continues the accounting treatment of the asset as set forth in the 2023 annual financial statements.

The following table illustrates the result of the reclassification showing amortization applied since December 31, 2022:

SCHEDULE OF FINITE LIVED INTANGIBLE ASSET

---

| | |
|:---|:---|
| **Cost, Amortization and Carrying Amount of the iTDE Technology** | **Cost, Amortization and Carrying Amount of the iTDE Technology** |
| **Cost** | |
| At December 31, 2022 | $3500127 |
| Additions |  |
| Transfers |  |
| At June 30, 2023 | 3500127 |
| Additions |  |
| Disposals | - |
| **At December 31, 2023** | **3500127** |
| Additions |  |
| Disposals | - |
| **At March 31, 2024** | **3500127** |
| **Accumulated Amortization** |  |
| At January 1, 2022 | 350013 |
| Charge for the year |  |
| At December 31, 2022 | 350013 |
| Charge for the year | 149782 |
| Prior Period Adjustment | 308365 |
| **At December 31, 2023** | **808160** |
| Charge for the period | 37446 |
| **At March 31, 2024** | **845606** |
| **Carrying amount** |  |
| At December 31, 2022 | 3150114 |
| At December 31, 2023 | 2691967 |
| **At March 31, 2024** | **2654522** |

---

**NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES**

As of March 31, 2024, and December 31, 2023, accounts payable and accrued liabilities consisted of as follows:

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

---

| | | |
|:---|:---|:---|
|  | March 31,<br>2024<br>(restated) | December 31<br>2023<br>(audited) |
| Accounts payable and accrued expenses | $803012 | $698009 |
| Accrued payroll | 1715842 | 1668748 |
| Accrued interest | 113278 | 76450 |
| Total | $2632132 | $2443207 |

---

As on March 31, 2024, the Company owed a total of $1,330,000 in loans payable to shareholders. None of these loans will fall due during fiscal 2024 and only two of these loans (including their various interest payments) will fall due during fiscal year 2025 (following extensions of such loans agreed as at the date of the filing of the present 10-Q/A).

&nbsp;&nbsp;&nbsp;&nbsp;(i) A loan of $125,000 will fall due September 14, 2025 and

&nbsp;&nbsp;&nbsp;&nbsp;(ii) A second loan of $125,000 will fall due September 14, 2025.

All the remaining loans outstanding on March 31, 2024 will fall due after fiscal year end 2025.

February 29, 2024, seven senior employees and consultants of the Company who were owed a total of $2,232,636 million on that date, agreed to defer payment by the Company of outstanding amounts owing to them on certain modified terms ("Debt Extension Agreements"). The Debt Extension Agreements replaced previous agreements and understandings relating to debt deferral and remuneration.

The Debt Extension Agreements were signed to cover all debts owing from time to time to the seven employees and consultants of the Company that were : (i) legitimately incurred unpaid contractual remuneration (ii) existing debts agreed and already deferred; (iii) advances made by the employee or consultant to the Company that are recorded on the books of the Company; (iv) any portion of employee's or consultant's agreed future remuneration that will not be paid in a timely fashion, all such debt being accumulated as a recognized debt in accordance with the terms of the Debt Extension Agreements.

The Debt Extension Agreements further set out the terms under which the seven employees and consultants would receive their past indebtedness as well as how future remuneration is to be paid. The Debt Extension Agreements also grant the right for each signatory to convert all or a portion of the Indebtedness and Penalty Interest to shares of common stock of the Company at any time at the lower of (i) the price which is five percent (5%) lower than the average trading price of the five business trading days immediately preceding the date of the election, or (ii), if the Company is in the process of raising finance and has made an offering to the public by reporting the offering to the Securities Exchange Commission ("SEC"), at the price that is five percent (5%) lower than the price recorded in such reported offering provided such offering shall have been active at any time during the previous quarter.

The indebtedness of the Company to the signatories of the Debt Extension Agreements shall be accelerated and become immediately due and payable in the event that the Company shall fail: (i) (a) to achieve an annual EBITDA of $5 million per annum, or, (b) to achieve a quarterly income figure of $12 million, or, (c) to declare the Indebtedness due, on or before February 28, 2027; or (ii) to pay the monthly remuneration agreed in the Agreement within 11 days of the month end in which the remuneration was incurred.

Notwithstanding the above, the Indebtedness shall become due on the fifth anniversary of the Debt Extension Agreements execution, being March 1, 2029.

By signature of an addendum with each of the signatories of the Debt Extension Agreements on May 30, 2025, the said agreements shall only enter into force on the first date following May 30, 2026 on which the total debt of the Company outstanding to any listed shareholders of NCX who are not employees of NCX has been either converted to shares of common stock of NCX, or paid in full, or forgiven; if this suspensive condition is not realized on or before May 30, 2026, each of the Debt Extension Agreements shall become void and cease to have effect.

As at June 30, 2025 none of these Debt Extension Agreements had entered into force.

All of the Directors, Officers, employees, consultants and professionals owed remuneration and expenses by the Company under the Debt Extension Agreements are considered important to the Company's operations and business. The Company holds agreements on the deferral of debt with seven of the above that will enter into force under certain conditions whereby the shareholder debtors agree to convert their debt into equity.

**NOTE 7 – CONVERTIBLE NOTES, PROMISSORY NOTES AND LOANS**

During the three months ended March 31, 2024, the Company issued five convertible notes with aggregate amount of $365,000 and will mature in 24 months.

As of March 31, 2024, the Company had eight outstanding loans with an aggregate value of $945,000. Each of these loans is repayable in one year and pays 10% interest annually in arrears. The Company contracted a further two loans during the three months ending March 31, 2024, with an aggregate value of $20,000. Each of these loans is repayable in one year and pays 10% interest annually at maturity.

During the three months ended March 31, 2024, the Company recognized interest expense on its loans and convertible notes of $36,827, as compared to $21,320 for the same period ended March 31, 2023.

**NOTE 8 – RELATED PARTY TRANSACTIONS**

The Company continues to rely on advances from related parties in support of its operations and cash requirements are expected to continue until such time as the Company can support itself or attain adequate financing through sales of equity or debt financing. Most of this support took the form of the nonpayment of all or a portion of salary payments to senior Directors, Officers, consultants, and employees, effectively constituting a deferred debt payment to such persons.

As of March 31, 2024, seven Directors, Officers and employees, including full time consultants, were owed a total of $2,232,636 for salaries, remuneration and expenses. Of this $364,415 is owed to the two Directors who are also the senior officers of the Company ("Senior Managers").

On March 31, 2024, the following Senior Managers were owed the following amounts:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Name | Title | Amount owing <br> ($) | Accumulated Leave<br> ($) | Total Liability <br> ($) |
| Benton Wilcoxon | Director, CEO | 56841 | 19930 | 76771 |
| John Michael Johnson | Director, President & CFO | 262698 | 24947 | 287645 |
| **Total Liability:** |  | 319539 | 44877 | **364415** |

---

Under the terms of the Debt Extension Agreements concluded between the Senior Managers and a further five other employees and consultants the outstanding debt to such persons may be converted under certain terms. In particular, such debt might be converted into shares at the price which is five percent (5%) lower than the average trading price of the five business trading days immediately preceding the date conversion or at the price that is five percent (5%) lower than the price reported to the SEC as an offering of shares to the market. In such event, the Company would be significantly diluted by the issuance of compensating shares. At March 31, 2024 the average 5-day trading price of the Company's shares was $4.50. If all the outstanding debt as at March 31, 2024 were to be converted at this price this would result in the issuance of 496,141 shares. If such option had been exercised on June 11, 2025 when the average 5-day trading price was $5.16 the number of shares to be issued would amount to 432,681 shares.

**NOTE 9 – VALUE OF FINANCIAL INSTRUMENTS**

As of March 31, 2024, the Company holds certain shares in the AIM publicly traded company Clontarf Energy plc. These shares were acquired on May 31, 2023 when the market price for such shares on AIM was GBP 0.00085. The table below sets forth the fair market value of the shareholding based on the closing price for the shares on the AIM market. As at March 31, 2024, the market price for Clontarf shares was GBP 0.00037, putting the Fair Value of the Investment at $44,957.

The Company recognized a loss of $56,568 on the shareholding when measured against the market price on the AIM market on the date of the acquisition of the shareholding.

From the acquisition Date to period cover March 31, 2024, the fair market value (FMV) of the shareholding was reported as follows:

SCHEDULE OF SHAREHOLDING MEASURED AGAINST THE MARKET PRICE

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Date** | **Number of Shares** | **Market Price** | **Exchange Rate** | **Amount in USD** |
| Acquisition Date | 31-May-23 | 96250000 | GBP 0.00085 | 1.24095 | 101525 |
| Period End | 31-March-24 | 96250000 | GBP 0.00037 | 1.26240 | 44957 |
| Unrealized (Loss) |  |  |  |  | (56568) |

---

For the three month period from January to March 2024, the FMV was reported as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Date** | **Number of Shares** | **Market Price** | **Exchange Rate** | **Amount in USD** |
| Year End, FMV | 31-Dec-23 | 96250000 | GBP 0.00053 | 1.27310 | 64944 |
| Period End | 31-March-24 | 96250000 | GBP 0.00037 | 1.26240 | 44957 |
| Unrealized(Loss) |  |  |  |  | (19987) |

---

**NOTE 10 – STOCKHOLDERS' EQUITY (DEFICIT)**

The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.001 and 5,000,000 shares of preferred stock with a par value of $0.001. There was no preferred stock issued and outstanding as of March 31, 2024.

On March 31, 2024, there were 28,546,834 shares of common stock outstanding.

During the three months ended March 31, 2024, the Company issued no shares of common stock.

During the three months ended March 31, 2024, the Company issued no options under the Company's 2021 Stock Incentive Plan (the "Plan").

During the three months ended March 31, 2024, the Company none of the outstanding convertible debt of the Company was converted into shares of common stock.

**NOTE 11 – SUBSEQUENT EVENTS**

The reader should refer to the Company's filing of its 2024 annual report on Form 10-K filed with the SEC on April 30, 2025 and its first quarter report on Form 10-Q/A filed on May 19, 2025 for a detailed account of subsequent events.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Overview**

The Company was organized on August 13, 2014, as a Nevada corporation under Chapter 78 of the Nevada Revised Statutes. The Company's registered address is 3773 Howard Hughes Pkwy STE 500S, Las Vegas, NV, 89169, USA, and its principal office is located at 1980 Festival Plaza Drive, Summerlin South, 300, Las Vegas, NV 89135.

The Company qualifies as an "emerging growth company" as defined in the Jumpstart Our Business Startups Act which became law in April 2012. The definition of an "emerging growth company" is a company with an initial public offering of common equity securities which occurred after December 8, 2011, and has less than $1 billion of total annual gross revenues during last completed fiscal year.

***Overview of the Business***

Since April 27, 2021, the Company has changed it business entirely with the acquisition of intellectual property assets related to a novel membrane-based ion extraction process ("iTDE Technology"), which is able to extract ions exiting in low concentrations from liquid solutions. The iTDE Technology is now being used in laboratory pilot testing to enable the Company to produce its first commercial prototypes using the novel the Extraction method. The iTDE Technology allows for the removal of ions from solution: without concentration by evaporation (significantly preserving the water resources); without pressure or additional heating (reducing energy costs); and targets the specific ions to be extracted (reducing the need for further operations and increasing the potential for the sale of other ions present in the solution). Because of the reduced interference with the environment, the lower energy costs, and the lack of a need for large evaporation ponds, management considers the iTDE Technology to be more environmentally friendly and sustainable when compared to alternatives.

The iTDE Technology has been shown effective when extracting lithium from brine solutions or mine leach solutions, and to have significant potential in the following applications: extracting fatty acids from vegetable oils as a superior refining process; extracting glycerides from biodiesel as a superior purification process; extracting radioactive ions from nuclear waste waters; extracting specific metal ions from mine leach solutions and waste effluents; and to remove salts from seawater for desalination, among other things.

Currently, the primary focus of the business is on completion of the first of two pilot plants embodying the iTDE Technology system that will enable the demonstration of the extraction system for the extraction of lithium, calcium, magnesium, boron, and certain other elements. The first system will provide greater flexibility to optimize and extend the reach of the process, allowing for replacement of sensor systems and variation of process parameters. It is anticipated that this pilot plant will not only demonstrate the system and its ability to target lithium using naturally occurring brines and liquors (solutions of crushed ores), but also provide a platform to optimize the extraction process and extend the extraction to other elements. The first pilot plant will enable the Company to establish the percentage level of extraction including the purity of the extracted elements and the chemical form of the extracted elements. This will give a clear indication of the economics of the process.

A second pilot plant system is planned using the experience from the first pilot plant to improve the current design enabling higher throughputs and a better processing ability for marketing purposes.

The Company believes it has the ability of the system to scale up due to its modular configuration: adding more units increases the extraction potential. It is anticipated following successful completion and trial and calibration of the iTDE System pilot plant, the Company will launch the commercial testing and deployment of its system that will enable the commercial deployment of the system.

On February 21 2024, in accordance with its obligations under the Partnership Agreement signed March 27, 2023, between the Company and the UK AIM listed company Clontarf Energy plc ("Clontarf"), the Company formed the certain partnership company as a Nevada LLC as required. The new LLC is the 50:50 joint venture between the Company and Clontarf that will be the vehicle for the proposed deployment of the Company's iTDE Technology in Bolivia. To date, the new LLC has not commenced direct activity, the partners undertaking any negotiations necessary to preserve the partnership's future rights. In this respect, on March 4 2024, Clontarf submitted the qualification materials for the partnership to the "Pública Nacional Estratégica Yacimientos de Litio Bolivianos" (the 'National Strategic Public Company of Bolivian Lithium Deposits' or "YLB") in relation to the Call for Bids ("convocatoria") for the seven priority salares (salt pans) in Southern Bolivia. Under the Partnership Agreement it is Clontarf's responsibility to submit such bids on behalf of the partnership LLC.

On May 14, 2024, the YLB confirmed Clontarf in the partnership with the Company as one of the twenty-one approved companies moving into phase three of the 'convocatoria' process, which consists of five phases. Phase two focused extensively on evaluating the lithium extraction technologies bidding, seeking in particular for direct lithium extraction methods, phase three will involve assessing the financial capacity of the bidders.

On January 26, 2024, the Corporate Secretary, an officer and full time of the Company, resigned and was replaced by the Company's President assuming the role of Corporate Secretary.

***Results of Operations***

The following table summarizes the results of our operations during the three months ended March 31, 2024, and 2023, respectively:

---

| | | | |
|:---|:---|:---|:---|
|  | For the Three Months Ended | For the Three Months Ended | |
|  | March 31, | March 31, | |
|  | 2024 | 2023 |<br>Change |
|  | (restated) | (unaudited) | |
| Revenues | $- | $- | $- |
| Operating expenses | 519581 | 436653 | 82928 |
| Other (Income) expense | 36827 | 21320 | 15507 |
| Net profit (loss) | (556408) | (457973) | 98435 |
| Profit (Loss) per share of common stock | (0.02) | (0.02) |  |

---

During the first quarter of 2024, operating expenses rose by $82,928 when compared to the same period of 2023. This was in part related to changes in the workforce with a reduction in full time salaried employees and a move to consultants. The US R&D wage bill was lower by $22,500 and the resignation of one officer lowered direct wages by a further 37,500, however this was more than offset by an increase of $99,143 in consultants and contractors. Part time and foreign based R&D consultants represents a strategic shift towards using part time expertise and an increase focus on conducting development in India. The Company has also seen minor increases the cost of certain third-party experts including its intellectual property managers and auditors. In addition, the Company recorded $41,397 in unused vacation time, the result of a small overworked number of key staff. The refocus of employment reflected by these changes represents a change in the strategy of the Company in general towards using lower cost expertise particularly focused on India to drive forward work on the iTDE System pilot plant, which necessitated payment of construction deposits and down payments. The Company also repaid certain indebtedness under promissory notes that became due however, interest due on debt increased from $21,320 in the first quarter of 2023 to $36,827 in the same quarter of 2024. Other expenses remain broadly the same.

***Liquidity and Capital Resources***

As of March 31, 2024, we had total current assets of $216,830 and an accumulated deficit of $7,068,518.

Our operating activities used $292,688 in cash for the three months ended March 31, 2024, while our operations used $310,145 cash in the three months ended March 31, 2023. During both periods, the Company has focused attention primarily on the work necessary to complete the pilot plants as it is considered strategically necessary to complete the pilot plants to enable the Company to move to the next stage of its marketing plan: to demonstrate the system and its extraction economics to potential users. Focus in this work was slowly shifted to conducting work in India. While the Company, has several companies interested in evaluating the system using their brines and these tests will consume a considerable amount of time once the pilot plants are ready to process. Management considers it preferable to focus on this work, and this has led to an overall reduction in expenses prior to reengaging in other activities.

During the three months ended March 31, 2024, the Company paid its employees and consultants less than in the same period in 2023 and was able to service part of its debts repaying $151 007 of its outstanding loans and interest. This was made possible by the receipt of proceeds from stock issuance and notes totaling $575,000. In contrast, during the first quarter 2024, the Company received an aggregate financing of $385,000 from notes and loans, insufficient to make the same payments to its employees. This shifted the burden of financing to employees and consultants and resulted in a net increase in amounts owing to such parties. During first quarter 2024, the Company recorded an unrealized loss of $19,987 resulting in the decline in the share price of Clontarf shares the Company holder. Since these were issued in May of 2023, this change is unmatched in the same period of 2023. The first quarter of 2024 also saw an increase in the use of consultants including legal services over the same period in 2023. Finally, the recategorization of the Company's principal asset and the application of amortization on its technology resulted in an increase in amortization expense of $37,446 over the reporting of the same period in 2023.

Our cash requirements continue to be primarily for the manufacture of the iTDE System pilot plant with the purchase of equipment, materials and operating expenses for the development of pilot plant systems, payroll, intellectual and other expenses. During the next six months that the Company plans to open new corporate offices and commence the organization of its initial production facility.

Historically we have depended on investment from our principal shareholders and their affiliated companies to provide us with working capital as required. There is no guarantee that such funding will be available when required and there can be no assurance that our stockholders, or any of them, will continue making loans or advances to us in the future.

***Off Balance Sheet Arrangements***

We do not have any off-balance sheet arrangements that have or are likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity or capital expenditures or capital resources that is material to an investor in our securities.

***Seasonality***

Our operating results are not affected by seasonality.

***Inflation***

The Company has in the past used funding from debt convertible equity as its primary source of funding. In the event of a high inflationary environment, this method of funding may become more expensive and may be less readily available. Our core business and operating results are not affected in any material way by inflation.

***Critical Accounting Policies***

Our financial statements and accompanying notes have been prepared in accordance with GAAP and all amounts recorded throughout this Report are stated in US dollars. The preparation of these financial statements requires management to make estimates, judgments, and assumptions that affect reported amounts of assets, liabilities, revenues, and expenses. We continually evaluate the accounting policies and estimates used to prepare financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are critical to our results of operations and financial position. Our critical accounting estimates are discussed in Note 2 to our unaudited financial statements contained herein.

**Item 3 - Quantitative and Qualitative Disclosures About Market Risk**

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

**Item 4 - Controls and Procedures**

**Disclosure of Controls and Procedures**

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including the Company's chief executive officer (who is the Company's principal executive officer) and the Company's President (who is the Company's chief operating officer) as well as its Financial Officer (the Company's principal financial officer) to allow for timely decisions regarding required disclosure. At present one person combines the roles of President and Chief Financial Officer. In designing and evaluating the Company's disclosure controls and procedures, the Company's management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and the Company's management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The ineffectiveness of the Company's disclosure controls and procedures was due to material weaknesses identified in the Company's internal control over financial reporting, described below.

**Management's Report on Internal Control over Financial Reporting**

Management is responsible for establishing and maintaining adequate internal control over the Company's financial reporting. To evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act of 2002. Our management, with the participation of the Company's principal executive officer and principal financial officer has conducted an assessment, including testing, using the criteria in Internal Control - Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") (2013). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. This assessment included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation.

Based on this evaluation, the Company's management concluded its internal control over financial reporting, while significantly improved, was still not effective as of March 31, 2024.

**Changes in Internal Control Over Financial Reporting**

Principal financial controls are managed by the Company's controller who maintains the accounts under the supervision of the Chief Financial Officer. At present the Company still relies on advances by officers and employees using their own means of payment to fund the Company, these are then repaid (or accumulated as debt) against an accounting of such expenses. The Company plans to issue its own means of payment in the future that would improve efficiency and transparency. The Company changed its bankers during the course of the third quarter 2023. While we believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any Company have been detected, the Company continues to improve its control environment with a view to establishing an effective control environment and to satisfying the Company auditors of the same.

**PART II**

**<u>OTHER INFORMATION</u>**

**Item 1 - Legal Proceedings**

On May 16, 2023, the Company received formal notice of a wage claim from the Illinois Department of Labor filed by a former consultant (1099) who had already resigned from the Company with an effective date of March 18, 2023. The consultant is claiming $7,292 as a final payment for the period from February 9 to March 15, 2023. The complaint was filed on March 16, 2023, without any notice being given to the Company. On March 18, 2023, the date the resignation was due to take effect, the Company paid the consultant $5,833 as the final remuneration covering the days worked during the period. On July 27, 2023, the consultant sent notice to the Company maintaining that the demand for the full amount of $7,292 as still due. The Company has approached the Consultant to attempt to reconcile the claim made against the remuneration paid, which appears manifestly incorrect, but the discussion was declined. On May 15, 2024, the case was dismissed by the Illinois Department of Labor.

On April 26, 2024, Judge Elizabeth Leonard of the Midland County District Court in Midland, Texas entered a Third Turnover Order (the "Turnover Order") requiring the Company to turn over 15,866,096 of its common shares, registered to a corporation with the same name as the Company (NEXT-ChemX Corporation) but registered in a different jurisdiction, to NEXT-ChemX Corporation, a Texas corporation, Glenn A. Little, as Director and Receiver. Sparkie Properties L.L.C. ("Sparkie") that is managed by Glenn Little who was also appointed receiver of, a privately held Texas corporation.

This decree was issued even though neither the privately held NEXT-ChemX Corporation, chartered in Texas, nor the Company itself was ever involved in the underlying lawsuit giving rise to said decree. This order arose from litigation in Sparkie Properties L.L.C. v. NextMetals Limited and Benton Wilcoxon, CV 58242, In the District Court of Midland County, Texas, 238<sup>th</sup> Judicial District. The shares of the Company owned by NEXT-ChemX Corporation, the privately held Texas Corporation, were alleged to belong to NextMetals Limited, a defendant in the litigation, rather than the aforementioned closely held Texas private company.

In fact, NextMetals Limited, a Gibraltar corporation defendant in the litigation does own shares in the closely held Texas private company, NEXT-ChemX Corporation, however the order has been issued to seize not the shares in the private Texas company but rather the private Texas company's assets, the shares in the Company. The similarity of names between the Company and the private Texas corporation came about in 2021 when the Company adopted the changed its business and adopted the name of its principal shareholder that has contributed the technology currently exploited by the Company in exchange for a controlling share. These facts were ignored by the Court; moreover, when the private Texas Company whose assets were under threat approached the Court to be heard, the Judge refused allow it a hearing and proceeded with the judgement effectively depriving the private Texas company of its asset.

The Turnover Order is not a final order as it is currently on appeal with the Texas Court of Appeals for the 11th District in Eastland, Texas.

When the Company received notice from its transfer agent, Empire Stock Transfer Inc. ("Empire") of Henderson, Nevada that, irrespective of the ongoing appeal of the Turnover Order and the fact that the shares covered by the Turnover Order were not the property of Sparkie Properties, L.L.C., Empire nevertheless advised the Company that it intended to issue the shares covered by the Turnover Order, the Company immediately terminated Empire as its transfer agent. This was done via an email and letter delivered on May 23, 2024, in which Empire acknowledged the receipt.

Although Empire no longer represented NEXT-ChemX Corporation, the Nevada public company, Empire promptly cancelled the shares owned by NEXT-ChemX Corporation, the closely held private corporation and issued 15,866,096 common shares in the public company divided into two certificates to NEXT-ChemX Corporation, a Texas corporation, Glenn A. Little, as Director and Receiver.

The Company and its attorneys believe the Turnover Order is illegal for reasons stated in a brief timely filed by attorneys for Benton Wilcoxon and NextMetals Ltd with the Texas Court of Appeals.

**Item 1A – Risk Factors**

Not applicable.

**Item 2 - Unregistered Sale of Equity Securities and Use of Proceeds**

None.

**Item 3 - Defaults upon Senior Securities**

None

**Item 4 - Mine Safety Disclosures**

Not applicable.

**Item 5 - Other Information**

None

**ITEM 6. EXHIBITS.**

The following exhibits are filed as part of this report or incorporated by reference:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 31.1\* | [Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-1.htm) |
| 31.2\* | [Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-2.htm) |
| 32.1\*\* | [Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-1.htm) |
| 101\* | Inline XBRL Document Set for the condensed financial statements and accompanying notes in Part I, Item 1, "Financial Statements" of this Quarterly Report on Form 10-Q/A. |
| 104\* | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q/A, included in the Exhibit 101 Inline XBRL Document Set. |

---

\* Filed herewith

\*\* Furnished herewith

**SIGNATURES**

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 30, 2025 | **NEXT-ChemX Corporation** | **NEXT-ChemX Corporation** |
|  | By: | */s/ Benton Wilcoxon* |
|  |  | Benton Wilcoxon |
|  |  | Chief Executive Officer |
|  |  | *(Principal Executive Officer)* |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION** 

I, Benton Wilcoxon, certify that:

1. I have reviewed this Form 10-Q/A of NEXT-ChemX Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

 a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: June 30, 2025 | By: | */s/ Benton Wilcoxon* |
|  |  | Benton Wilcoxon |
|  |  | Principal Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION** 

I, J. Michael Johnson, certify that:

1. I have reviewed this Form 10-Q/A of NEXT-ChemX Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: June 30, 2025 | By: | */s/ J. Michael Johnson* |
|  |  | J. Michael Johnson |
|  |  | Principal Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER**

**PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with this Quarterly Report of NEXT-ChemX Corporation (the "Company"), on Form 10-Q/A for the period ended March 31, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, Benton Wilcoxon, Principal Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;(1) Such
 Quarterly Report on Form 10-Q/A for the period ended March 31, 2024, fully complies with the requirements of section 13(a) or 15(d)
 of the Securities Exchange Act of 1934; and

(2) The
 information contained in such Quarterly Report on Form 10-Q/A for the period ended March 31, 2024, fairly presents, in all material
 respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: June 30, 2025 | By: | */s/ Benton Wilcoxon* |
|  |  | Benton Wilcoxon |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |

---

In connection with this Quarterly Report of NEXT-ChemX Corporation (the "Company"), on Form 10-Q/A for the period ended March 31, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, J. Michael Johnson, Principal Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;(1) Such
 Quarterly Report on Form 10-Q/A for the period ended March 31, 2024, fully complies with the requirements of section 13(a) or 15(d)
 of the Securities Exchange Act of 1934; and

(2) The
 information contained in such Quarterly Report on Form 10-Q/A for the period ended March 31, 2024, fairly presents, in all material
 respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: June 30, 2025 | By: | */s/ J. Michael Johnson* |
|  |  | J. Michael Johnson |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial Officer and Principal Accounting Officer) |

---